PerkinElmer Launches Industry First No-Wash Immunoassay For Phospho Ubiquitin Ser65 to Help Drive Neuroscience Disease and Therapeutics Research Forward
26.10.2020 22:05:00 EET | Business Wire | Press release
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today launched the life science industry’s first no wash Ubiquitin phosphorylation at Serine 65 immunoassay for studying defective mitophagy biological mechanisms that have been broadly associated with diseases such as Parkinson’s and Alzheimer’s. The new PerkinElmer Cisbio HTRF® Phospho-Ubiquitin (Ser65) Cellular Kit takes analysis efficiency and accuracy to the next level compared to existing techniques such as Western blot and is aimed at helping scientists discover new therapeutic candidates earlier in the disease cycle.
The innovative assay leverages TR-FRET technology to bring high sensitivity across a wide range of analytes and greater study specificity to the Phospho-Ubiquitin (Ser65) intersection point that has been shown to play a key role in mitophagy dysfunction and breakdowns in the complex network between neurons and glial cells which can lead to neurodegenerative disease.
Efficient and streamlined workflows and accelerated data delivery are also provided by the immunoassay’s mix and read method approach and compatibility with microplate readers such as PerkinElmer’s VictorTM Nivo® or EnVision® systems. Analysis can also be automated and run in high throughput formats.
“With over 70 Million people around the world living with Alzheimer’s and Parkinson’s and the sheer complexity of how neurodegenerative disease develops in the brain, it is critical that scientists have the tools they need to help unlock promising avenues of study such as modulating mitophagy impairment,” said Alan Fletcher, VP and GM of Life Sciences, PerkinElmer. “With this new immunoassay, researchers now have a more efficient and effective way to study a key biomarker which could lead to exciting new therapeutic candidates.”
The new PerkinElmer Cisbio HTRF Phospho-Ubiquitin (Ser65) Cellular Kit, joins PerkinElmer’s range of immunoassay kits and reagents for neuroscience applications across HTRF, Alpha, LANCE® and DELFIA®. For more information please visit: https://learn.cisbio.com/lp/guide-neurodegenerative-diseases-and-neuroinflammation-pathways; https://uk.cisbio.eu/dd/by-universe/neuroscience
About PerkinElmer
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005820/en/
Contact information
Jennifer McNeil
+1 508 380 2902
Jennifer.mcneil@perkinelmer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dryad Wins International XPRIZE Wildfire Award for Autonomous Wildfire Detection and Suppression23.9.2026 20:00:00 EEST | Press release
Dryad Networks, a leader in ultra-early wildfire detection, today announced it has been awarded $800,000 in the XPRIZE Wildfire competition for its performance in the Autonomous Wildfire Response finals in Alaska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923024178/en/ Silvaguard Observation and Suppression drone and Hangar Dryad advanced from an original field of approximately 300 entrants in the four-year competition. In June 2026, three finalists were challenged to autonomously detect and completely suppress a high-risk wildfire within 10 minutes of ignition across 1,000 km² of Alaskan wilderness, leaving any decoy fires untouched. It was the most demanding live test to date of what it will take to stop a destructive fire before it grows out of control. During the tests, the Dryad’s Silvanet sensor network successfully detected and verified target fire in 12 minutes or less and autonomously launched a response, ig
SES Appoints Michel Scholer to Board of Directors23.9.2026 19:54:00 EEST | Press release
SES today announced the appointment of Mr. Michel Scholer, Secretary General of the Luxembourg Government and Chief of Staff to the Prime Minister, to its Board of Directors effective immediately. This appointment is part of SES’s Board succession planning and ongoing commitment to regularly review and strengthen the composition of its Board with diverse expertise and industry experience, ensuring the company is well positioned for future growth and value creation. Prior to his current role with the Luxembourg Government, Mr. Scholer served as a Senior Adviser to the International Monetary Fund, and with the Ministry of Finance, Luxembourg. He was nominated for the SES Board of Directors by the Government of the Grandy Duchy of Luxembourg. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, bus
Future Health - A Global Initiative by Abu Dhabi: New Analysis Estimates Modifiable Health Risks Represent $16.4 Trillion Annual Global GDP Opportunity in 205023.9.2026 19:50:00 EEST | Press release
Addressingbehavioural, metabolic and environmental health risks could generate an estimated $16.4 trillion in annual global GDP uplift in 2050. These findings are presented in The Future of Healthy Living: A $16.4 Trillion Opportunity, a new whitepaper co-authored by Future Health – A Global Initiative by Abu Dhabi, the McKinsey Health Institute (MHI) and Healthy Living at the Department of Health – Abu Dhabi, and released on the sidelines of the 81st Session of the United Nations General Assembly (UNGA 81) in New York. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923530109/en/ A new whitepaper by Future Health – A Global Initiative by Abu Dhabi, in collaboration with the McKinsey Health Institute, estimates that eliminating modifiable health risks could deliver substantial health and economic benefits The publication comes as governments look to translate the UN Political Declaration on Noncommunicable Diseases and Men
SES Confirms Interim Dividend of EUR 0.2523.9.2026 19:46:00 EEST | Press release
The SES Board of Directors has approved the payment of an interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) to be paid to shareholders on October 15, 2026, in line with SES’s commitment to shareholder returns. The interim dividend to be paid in October 2026 will be followed, subject to financial results and shareholder approval, by the payment of a final dividend of at least EUR 0.25 per A-share (EUR 0.10 per B-share) in May 2027. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer
Nomios Expands Presence in Southern Europe with Leading Portuguese Cybersecurity Services Specialist Orbcom23.9.2026 17:30:00 EEST | Press release
Nomios, a pan-European specialist in cybersecurity services, announces the acquisition of Orbcom, a leading Portuguese provider of cybersecurity services and IT consulting solutions with about €15 million of yearly revenue and 80 FTEs. Orbcom is one of the few partners with Diamond Innovator status within the Palo Alto Networks NextWave Partner Program in Portugal and a key partner of Netskope, Infoblox and Arista. The acquisition marks another milestone in Nomios’ European expansion, establishing the Group’s first foothold in Portugal and further reinforcing its position as the trusted cybersecurity partner for organisations across Europe. Strengthening our security expertise with key vendor relationships Nomios supports organisations across Europe in securing their critical digital infrastructures, whether on-premise or cloud based. Nomios’ approach is structured around three core service pillars. Through its Consulting Services, the group provides strategic advisory and tailored sup
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom